Natera presented real‑world data at ASH showing that circulating tumor DNA (ctDNA) positivity at end of treatment was prognostic across lymphoma subtypes and performed better than PET imaging for predicting outcomes. Investigators reported that end‑of‑treatment ctDNA status stratified relapse risk and correlated with survival outcomes more consistently than PET in the datasets shown. The result underscores growing interest in liquid‑biopsy MRD assays to inform post‑treatment decision making and supports efforts to qualify ctDNA endpoints for regulatory use. Payers and trial designers will watch how assay standardization, turnaround time and integration with imaging influence uptake in lymphoma development programs.